Mauna Kea Technologies SA (ALMKT.PA) Stock
Mauna Kea Technologies SA

Company profile
Mauna Kea Technologies SA reported revenue of 7.66 million EUR for fiscal year 2024, down 27.0% from fiscal year 2023. United States & Canada was its largest region in fiscal year 2024, with 45% of revenue. Our analysis of its filings shows revenue growing from 7.48 million EUR in fiscal year 2022 to 7.66 million EUR in fiscal year 2024, 1.2% a year on average. Mauna Kea Technologies SA reports about 56 full-time employees.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss widened from 3.73 million EUR in fiscal year 2023 to 10.40 million EUR in fiscal year 2024.
- Asia brought in 29% of revenue by region in fiscal year 2024, down from 42% in fiscal year 2023.
- Its average diluted share count rose 12.9% in fiscal year 2024, from 62.1 million to 70.1 million shares.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Mauna Kea Technologies SA
Mauna Kea Technologies SA manufactures and sells medical devices in Europe, Middle East, Africa, the United States, Canada, and Asia. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables physicians to monitor disease progression over time, assess reactions as they occur, classify areas of uncertainty, and guide surgical procedures, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.
Largest shareholders
- Vester Finance SA17.40%
- European Investment Bank8.96%
- Telix Pharmaceuticals Limited6.10%
- Johnson & Johnson Innovation - JJDC, Inc.5.54%
- OFI Invest Asset Management SA2.34%
Share of the company, as of September 25, 2026
Leadership
- Alexandre Loiseau Ph.D. — Co-Founder, CEO & Chairman
- Daryl Donatelli — President of U.S. & Head of Global Marketing
- Come de La Tour du Pin — Chief Financial Officer
- Nathalie Lecoq — Chief Operating Officer
- François Lacombe Ph.D. — Chief Scientific Officer
How much revenue does Mauna Kea Technologies SA make?
Mauna Kea Technologies SA reported 7.66 million EUR in revenue for fiscal year 2024, down 27.0% from 10.48 million EUR in fiscal year 2023.
Where does Mauna Kea Technologies SA make most of its revenue?
United States & Canada: 45% of revenue by region in fiscal year 2024, followed by Asia (29%).
What companies are similar to Mauna Kea Technologies SA?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Lumibird SA (LBIRD.PA), Theraclion SA (ALTHE.PA).
Has Mauna Kea Technologies SA made a profit in recent years?
Net income by fiscal year: FY2020, a loss of 12.79 million EUR; FY2021, a loss of 13.45 million EUR; FY2022, a loss of 11.18 million EUR; FY2023, a loss of 3.73 million EUR; FY2024, a loss of 10.40 million EUR. It reported a net loss in each of these 5 years.
How has Mauna Kea Technologies SA's revenue by region changed?
Share of revenue by region in fiscal years 2023 and 2024: United States & Canada, 43% and 45%; Asia, 42% and 29%; EMEA, 15% and 26%.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Mauna Kea Technologies SA (ALMKT.PA)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/ALMKT.PA